American Psychiatric Association (2000a). Practice guidelines for the treatment of patients with eating disorders. Am J Psychiatry 157(Suppl):1-39.

American Psychiatric Association (2000b). Practice guidelines for the treatment of patients with major depression. Am J Psychiatry 157(Suppl):1-45.

American Psychiatric Association (2001a). Practice guidelines for the treatment of patients with borderline personality disorder. Am J Psychiatry 158(Suppl):1-52.

American Psychiatric Association (2002). Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159(Suppl):1-50.

Breggin PR (1997). Psychotherapy in emotional crises without resort to psychiatric medications. Humanistic Psychologist 25:2-14.

DeBattista C, Solvason HB, Breen H, et al. (2000). Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychiatry 20:274-275.

Doidge N, Simon B, Gillies LA, Ruskin R (1994). Characteristics of psychoanalytic patients under a nationalized health plan: DSM-III-R diagnoses, previous treatment, and childhood trauma. Am J Psychiatry 151:586-590.

Donovan SJ, Roose SP (1995). Medication use during psychoanalysis: A survey. J Clin Psychiatry 56:177-178.

Eissler KR (1953). The effect of the structure of the ego on psychoanalytic technique. J Amer Psychoanalytic Assn 1:104-143.

Foa EB, Franklin ME (2000). Psychotherapies for obsessive-compulsive disorder: A review. In Maj M, Sartorius N, Okasha A, et al. (eds). Obsessive-Compulsive Disorder, Vol. 4, Wiley: Chichester, England, pp. 93 -115.

Freud A (1966). The Ego Mechanisms of Defense. International Universities Press: New York.

Freud S (1895). Project for a Scientific Psychology. Standard Edition. Hogarth Press: London, Vol. 1, pp. 283-391.

Freud S (1933). Lecture 31, The Dissection of the Psychical Personality. Standard Edition. Hogarth Press: London, Vol. 22, p. 80.

Freud S (1933). Lecture 34, Explanations, Applications, and Orientations. Standard Edition. Hogarth Press: London, pp. 153 -154.

Freud S (1937). An Outline ofPsychoanalysis. Standard Edition. Hogarth Press: London, Vol. 23, p. 195.

Freud S (1937-39): An Outline of Psychoanalysis. Standard Edition. Hogarth Press: London, Vol. 23, p. 182.

Gabbard GO, Gunderson JG, Fonagy P (2002). The place of psychoanalytic treatments within psychiatry. Arch Gen Psychiatry 59:505-510.

Garland EJ, Baerg EA (2001). Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adol Psychopharmacol 11:181-186.

Gardner R (2001). Evolutionary perspectives on stress and affective disorder. Sem Clin Neu-ropsychiatry 6:32-42.

Gray SH (1996). Developing practice guidelines for psychoanalysis. J Psychotherapy Practice Res 5:213-227.

Hartmann H (1951). Technical implications of ego psychology. Psychoanalytic Quart 20:31-43.

Hoehn-Saric R, Harris GJ, Pearlson GD, Cox CS (1991). A fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. J Clin Psychiatry 52:131-133.

Ikemoto S, Panksepp J (1999). The role of nucleus accumbens dopamine in motivated behavior: A unifying interpretation with special reference to reward-seeking. Brain Res Rev 31:6-41.

Izumi T, Inoue T, Kitagawa N, et al. (2000). Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affective Disorders 61:127-132.

Kaplan MJ (2000). Atypical antipsychotics for mixed depression and anxiety. J Clin Psychiatry 61:388-389.

Keller MB, McCullough JP, Klein DN, et al. (2000). A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New Engl J Med 342:1462-1470.

Nersessian E (1992). The use of medication in patients who are in analysis. J Clin Psychoanalysis 1:41-45.

Ostow M (1990). On beginning with patients who require medication. In Rothstein A (ed). On Beginning an Analysis. International Universities Press: Madison, CT, pp. 201-227.

Ostow M (1993). How does psychiatric drug therapy work? In Schachter M (ed). Psychotherapy and Medication: A Dynamic Integration. Jason Aronson: Northvale, NJ, p. 133.

Ostow M (2002). Use of dreams by psychopharmacologists (letter). Am J Psychiatry 159:319320.

Panksepp J (1998). Affective Neuroscience: The Foundations of Human and Animal Emotions. Oxford University Press: New York.

Roth A, Fonagy P (1996). What Works for Whom? A Critical Review of Psychotherapy Research. Guilford Press: New York.

Shevrin H (2001). Drug dreams: An introduction. JAPA 49:27-56.

Solms M, Turnbull O (2002). The brain and the inner world: An introduction to the neuroscience of subjective experience. Other Press: New York.

Sporn J, Ghaemi SN, Sambur MR, et al. (2000). Pramipexole augmentation in the treatment of unipolar and bipolar depression. Annals Clin Psychiatry 12:137-140.

Stern RH, Roose SP (1995). Medication use in training cases: A survey. JAPA 43:163-170.

Stone L (1954). The widening scope of indications for psychoanalysis. JAPA 2:567-594.

Wallerstein RS (1986). Forty-Two Lives in Treatment. Guilford Press: New York.

Wallerstein RS (1996). Outcomes of psychoanalysis and psychotherapy at termination and at follow-up. In Nersessian R, Kopff RG (eds). Textbook of Psychoanalysis. American Psychiatric Press: Washington, DC.

Weinshel EM (1990). How wide is the widening scope of psychoanalysis and how solid is its structural model? Some concerns and observations. JAPA 38:275-296.

Willick MS (2001). Psychoanalysis and schizophrenia: A cautionary tale. JAPA 49:69-73.

Wylie H, Wylie M (1995). Resistances and obstructions: Their distinction in psychoanalytic treatment. J Clinical Psychoanalysis 4:185-207.

Anxiety Away

Anxiety Away

The strategies revealed within Anxiety Away are fast acting, simple and guaranteed to work even if you have suffered from anxiety for a long time!

Get My Free Ebook

Post a comment